

# Resa K. Schlossberg

Skadden

Partner, New York

Intellectual Property and Technology



T: 212.735.3467  
resa.schlossberg@skadden.com

## Education

J.D., Columbia Law School, 2004  
(Harlan Fiske Stone Scholar)  
B.S., Yale University, Molecular  
Biophysics and Biochemistry, 2001

## Bar Admissions

New York  
U.S. Patent and Trademark Office

Resa Schlossberg is head of Skadden's intellectual property and technology transactions practice. She advises clients in numerous industries on a wide range of IP-related issues, focusing on life sciences and technology-intensive representations. Her knowledge of molecular biophysics and biochemistry and research experience allow her to understand the scientific and technical aspects of matters.

Ms. Schlossberg structures, drafts, negotiates and advises on joint ventures, strategic alliances, mergers and acquisitions, and agreements such as license, research and development (R&D), collaboration, co-marketing and co-promotion, manufacturing and supply, R&D funding, synthetic royalty deals and consulting. She also conducts IP diligence and evaluates technologies for clients, including pharmaceutical, chemical, biotechnology, cosmetic, medical device and renewable energy companies, among others.

In addition to transactional work, Ms. Schlossberg has significant experience litigating patent infringement disputes in U.S. federal court, representing clients in false advertising and consumer deception matters and counseling on various strategic IP issues. She is a registered patent attorney with the U.S. Patent and Trademark Office.

Ms. Schlossberg was named one of the Top 250 Women in IP and a Transactions Star by *Managing IP* in 2024 and 2023, recognized among LMG Life Sciences' top practitioners for Licensing & Collaboration and Mergers & Acquisitions, and selected to *Intellectual Asset Management's IAM Patent 1000*, where she is described as a "master at executing a deep dive into target and competitor portfolios, formulating strategies, structuring deals and successfully negotiating them." She has also been named one of Lawdragon's 500 Leading Global IP Lawyers.

Representative transactions include:

- **Achillion** in its \$930 million sale to Alexion
- **Air Products** in its \$1.81 billion sale of its LNG business to Honeywell
- **Alcon** in its \$753 million acquisition of Aerie Pharmaceuticals, Inc. and its \$355 million acquisition of the U.S. commercialization rights to SIMBRINZA from Novartis AG
- **Alder BioPharmaceuticals** in its sale to Lundbeck for up to \$1.95 billion
- **Alnylam Pharmaceuticals, Inc.** in its \$2.8 billion co-development and co-commercialization agreement with Roche Holding AG to develop and commercialize its hypertension drug Zilebesiran
- **Ambrx Biopharma** in its \$2 billion acquisition by Johnson & Johnson
- **Amicus Therapeutics, Inc.** in ARYA Sciences Acquisition Corp IV's acquisition of Amicus' gene therapy business
- **Anokion** in its exclusive strategic collaboration with Celgene to develop novel tolerance-inducing therapeutics for autoimmune diseases
- **ArQuile** in its \$2.7 billion sale to Merck
- **Array Biopharma, Inc.** in its strategic collaborations with Bristol-Myers Squibb and Merck
- **Aspen Technology** in its \$11 billion merger with Emerson Electric Company's software business units

# Resa K. Schlossberg

Continued

- **BELLUS Health Inc.** in its \$2 billion acquisition by GSK plc
- **Berry Global Group** in its merger with Amcor plc
- **BridgeBio Pharma, Inc.** in its \$1 billion acquisition of all the outstanding common stock of Eidos Therapeutics, Inc. that it did not already own
- **Brookfield Super-Core Infrastructure Partners** in its \$2.4 billion acquisition of a 19.9% minority interest in FirstEnergy Transmission, LLC
- **ByteDance** in its investment and business cooperation agreement with For Fun Labs, Inc. and various other transactions
- **Catalent** in its acquisition by Novo Holdings in an all-cash transaction valued at \$16.5 billion, as well as its sales of facilities to both Pace Life Sciences and Ardena
- **Celularity** in its acquisition by GX Acquisition Corp., a special purpose acquisition company
- **CerSci Therapeutics Inc.** in its acquisition by ACADIA Pharmaceuticals Inc. for \$53 million upfront and contingent payments of \$887 million
- **DE Shaw Renewables** in an acquisition of a minority stake by Macquarie Group
- **DENTSPLY SIRONA Inc.** in its \$131 million acquisition of substantially all of the assets of Propel Orthodontics, LLC
- **Dicerna Pharmaceuticals, Inc.** in its acquisition by Novo Nordisk A/S at an equity value of \$3.3 billion
- **Dover Corporation** in the pending \$2 billion sale of its Environmental Solutions Group business to Terex Corporation
- **DowDuPont** in its separation into three independent public companies
- **DuPont** in several matters, including its merger of its Nutrition and Health Business with IFF through a reverse Morris trust transaction; \$11 billion sale of the majority of its Mobility & Materials (M&M) business to Celanese Corp.; and sale of a portion of its crop protection business to FMC Corporation in exchange for substantially all of FMC's health and nutrition business and a balancing payment of \$1.625 billion
- **Exelixis** in its exclusive clinical development collaboration and option agreement with Sairopa to develop ADU-1805
- **Endo Pharmaceuticals** in various strategic collaborations, acquisitions and other matters, including its sale of its men's health business to Boston Scientific and its acquisition of Penwest Pharmaceuticals
- **Everest Medicines Limited** in its \$451 million IPO of shares and listing on the Hong Kong Stock Exchange

- **EyeBio** in its acquisition by Merck for a \$1.3 billion upfront payment and up to \$1.7 billion in future milestone payments equaling a potential value of \$3 billion
- **FaZe Clan Inc.** in its \$1 billion combination with special purpose acquisition company B. Riley Principal 150 Merger Corp.
- **FREYR Battery** in its acquisition of Trina Solar's U.S. manufacturing assets
- **Gain Therapeutics, Inc.** in its \$40 million IPO of common stock
- **Gilead Sciences** in its \$4.9 billion acquisition of Forty Seven, \$11.9 billion acquisition of Kite Pharma and acquisition of Cell Design Labs for up to \$567 million
- **GX Acquisition Corp.** in its merger with Celularity Inc. at an enterprise value of \$1.7 billion. As a result of the merger, Celularity became a publicly traded company
- **Hasbro** in its \$522 million acquisition of Saban Brands' "Power Rangers" and other entertainment assets
- **Holcim, Ltd.** in its pending separation of its North American businesses into a new stand-alone company
- **Honeywell** in its acquisition of Carrier Global Corporation's Global Access Solutions business for \$4.95 billion and acquisition of CAES Systems Holdings LLC from private equity firm Advent International
- **IFF** in the pending \$2.9 billion sale of its pharma solutions business to Roquette and the \$810 million sale of its cosmetics ingredients business to Clariant
- **Intercept Pharmaceuticals, Inc.** in various capital markets matters
- **Iora Health** in its \$2.1 billion acquisition by One Medical
- **IVERIC bio, Inc.** in its \$5.9 billion acquisition by Astellas Pharma Inc.
- **Juno Therapeutics, Inc.** in its acquisition by Celgene Corporation, valuing Juno at over \$11 billion
- **a life sciences startup** in a sponsored research agreement with an academic institution
- **Lyell Immunopharma, Inc.** in its acquisition of ImmPACT Bio USA Inc., a privately owned clinical-stage cell therapy company
- **Medigene AG** in its multi-target research collaboration with BioNTech Se to develop T cell receptor (TCR)-based immunotherapies against cancer
- **Morphosys** in its purchase by Novartis for an aggregate of €2.7 billion in cash
- **Nano-X Imaging Ltd** in its initial public offering

## **Resa K. Schlossberg**

Continued

- 
- **OceanSound Partners, LP** in its strategic investment in Lynx Software Technologies and various other transactions
  - **Orum Therapeutics** in Bristol-Myers Squibb's acquisition of Orum's ORM-6151 leukemia antibody treatment program
  - **Pandion Therapeutics** in its pending \$1.8 billion sale to Merck
  - **Permira Funds** in several acquisitions, including of Cambrex Corporation, a majority stake in Reformation and Lyophilization Services of New England, Inc., as well as the sales of its portfolio companies Atrum Innovations and PHARMAQ Holding AS
  - **Pfizer Inc.** in its proposed \$160 billion combination with Allergan; proposed but withdrawn \$115 billion acquisition of AstraZeneca through the formation of a new U.K. holding company; IPO of its animal health business and related R&D collaboration and license agreement and IP license agreements between Pfizer Inc. and Zoetis Inc.; R&D agreements with NovaQuest and RPI Finance Trust; exclusive agreement granting AROG Pharmaceuticals worldwide rights to a small molecule inhibitor of PDGFr; and collaboration to co-develop Tremelimumab for advanced melanoma
  - **Population Council** in its license agreement with TherapeuticsMD
  - **Purdue Pharma L.P.** in its sale of an active pharmaceutical ingredient (API) manufacturing facility and corresponding negotiation of a long-term API supply agreement with the facility purchaser and an agreement with stalking horse bidder Atlantis Consumer Healthcare to sell the assets of Avrio Health L.P. for up to \$397 million via an auction process pursuant to Section 363 of the Bankruptcy Code
  - **Stemline Therapeutics** in its sale to Menarini Group for up to \$677 million
  - **Stryker Corporation** in its acquisition of privately held CHG Hospital Beds, Inc. and various other matters
  - **TriRx Pharmaceutical Services** in its acquisition of the French manufacturing and packaging operations of Merck & Co., Inc.'s animal health business and a related long-term supply agreement
  - **Vertex Pharmaceuticals** in its \$950 million acquisition of Semma Therapeutics and \$320 million acquisition of ViaCyte
  - **vTv Therapeutics Inc.** (a MacAndrews & Forbes portfolio company) in its collaboration, license and investment arrangements with affiliates of G42 Healthcare, and its investment and services arrangement with CinRx Pharma
  - **VYNE Therapeutics Inc.** in its \$50 million offering of common stock
  - **Wendel SE** in its \$910 million acquisition of Crisis Prevention Institute from FFL Partners